Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2016

View Archived Issues

Patients with atopic dermatitis dosed in phase I trial of MOR-106

Mouse model created using VPS35 gene mutation linked to Parkinson's disease

Intra-Cellular reports topline results from second phase III study of ITI-007 in schizophrenia

Tracon Pharmaceuticals starts collaboration with Janssen for TRC-253 and TRC-694

NAMPT may be useful as a biomarker for PD

Amgen reports topline data from phase III ARISE trial of erenumab to prevent episodic migraine

miRNAs show potential as biomarkers in liver fibrosis

CD1a is a potential new therapeutic target in inflammatory skin disease

The long non-coding RNA Morrbid is a promising new therapeutic target for inflammatory disorders

Eleventa completes patient enrollment for phase III trial of timapiprant

Adaptimmune Therapeutics and MD Anderson form cancer immunotherapy alliance

Pfizer completes acquisition of Medivation

Cellular Dynamics International launches new venture, Opsis Therapeutics

4SC Discovery patents KCNA3 channel blockers

Daiichi Sankyo to acquire license for technology platforms from Zymeworks

Marinus reports promising data from phase II trial of ganaxolone in PCDH19 pediatric epilepsy

Arbutus Biopharma reports interim results from phase II trial of ARB-1467 in chronic HBV

Vectus Biosystems reports development of vasodilating agents

Dermata Therapeutics reports findings from phase I trial of DMT-210 in acne rosacea

Kyung Hee University describes mPGES-1 inhibitors

Aurigene Discovery Technologies presents CDK inhibitors

Washington University announces HGFA inhibitors

11beta-HSD1 inhibitor alleviates muscle pain and mechanical allodynia in vivo

Phase IIb trial of Genocea's GEN-003 achieves primary endpoint

Recombinant human lubricin improves symptoms of dry eye disease

Amgen and Arrowhead Pharmaceuticals sign cardiovascular license and collaboration agreements

Hanmi Pharmaceutical enters agreement with Genentech

Mikeluna approved in Japan for glaucoma and intraocular hypertension

First patient dosed in phase I clinical study of PF-06840003

Boehringer Ingelheim and ViraTherapeutics to develop next generation oncolytic virus platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.